Overview

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid